logo for Corcept Therapeutics

Corcept Therapeutics

Manufacturing · California, United States · 352 Employees

View Company Info for Free

About

Headquarters

149 Commonwealth Dr, Menlo Park, California, 94...

Phone Number

(650) 327-3270

Revenue

$523.5 Million

Stock Symbol

CORT

Industry

Pharmaceuticals Healthcare

Highlights

$119M

Total Funding Amount

$41.9M

Most Recent Funding Amount

4

Number of Funding Rounds

Who is Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, o ncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushings syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park,...Read more

Corcept Therapeutics's Social MediaPopular SearchesCorcept Therapeuticscorcept therapeutics IncCorcept Therapeutics - IncCorceptCorcept Therapeutics Incorporated Q1SIC Code 28,283NAICS Code 32,325Ticker NASDAQ: CORTShow more

Corcept Therapeutics Org Chart

Joseph Belanoff
Joseph Belanoff

Chief Executive Officer

PhoneEmail
Atabak Mokari
Atabak Mokari

Chief Financial Officer

PhoneEmail

PhoneEmail

PhoneEmail

Similar Companies to Corcept Therapeutics

See more similar companies
Illustration of an envelope

Corcept Therapeutics Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateJan 27, 2011
RoundStock Issuance/Offering
Amount$41.9M
InvestorsUndisclosed
Funding DateOct 13, 2009
RoundStock Issuance/Offering
Amount$18M
InvestorsLongitude Capital, Sutter Hill Ventures, Alta Partners, Kaufmann Funds
Funding DateAug 16, 2007
RoundStock Issuance/Offering
Amount$10.1M
InvestorsPaperboy Ventures, Sutter Hill Ventures, Alta Partners
See More

$119M

Total Funding Amount

$41.9M

Most Recent Funding Amount

4

Number of Funding Rounds

Corcept Therapeutics Tech Stack

A closer look at the technologies used by Corcept Therapeutics

Top Companies in United States

Top 10 companies in United States by revenue

Top 10 companies in United States by number of employees

Top 10 companies in United States by total funding amount

See top companies

Most Recent Scoops

Jun 12 2024
Open Position
May 17 2024
Hiring Plans
May 15 2024
Open Position
May 14 2024
Open Position
May 8 2024
Facilities Relocation / Expansion
Corcept Therapeutics is planning to move offices in June 2024. The move will impact approximately 7 employees at the existing office located at 149 Commonwealth Dr, Suite #1001, Menlo Park, CA.
Facilities Relocation/Expansion
See more scoops

Corcept Therapeutics News & Media

Read more news

Frequently Asked Questions regarding Corcept Therapeutics

Where is Corcept Therapeutics located?
Corcept Therapeutics's headquarters are located at 149 Commonwealth Dr, Menlo Park, California, 94025, United States
What is Corcept Therapeutics's phone number?
Corcept Therapeutics's phone number is (650) 327-3270
What is Corcept Therapeutics's stock symbol?
Corcept Therapeutics's stock symbol is CORT
What is Corcept Therapeutics's official website?
Corcept Therapeutics's official website is www.corcept.com
What is Corcept Therapeutics's Revenue?
Corcept Therapeutics's revenue is $523.5 Million
What is Corcept Therapeutics's SIC code?
Corcept Therapeutics's SIC: 28,283
What is Corcept Therapeutics's NAICS code?
Corcept Therapeutics's NAICS: 32,325
How many employees does Corcept Therapeutics have?
Corcept Therapeutics has 352 employees
What industry does Corcept Therapeutics belong to?
Corcept Therapeutics is in the industry of: Pharmaceuticals, Healthcare
What is Corcept Therapeutics competition?
Corcept Therapeutics top competitors include: ACADIA Pharmaceuticals, Supernus Pharmaceuticals, Vanda Pharmaceuticals, Intra-Cellular Therapies
What technology does Corcept Therapeutics use?
Some of the popular technologies that Corcept Therapeutics uses are: DocuSign, WordPress.org, Drupal, reCAPTCHA
Who is the CEO of Corcept Therapeutics?
Corcept Therapeutics's CEO is Joseph Belanoff
Who is the CFO of Corcept Therapeutics?
Corcept Therapeutics's CFO is Atabak Mokari
How do I contact Corcept Therapeutics?
Corcept Therapeutics contact info: Phone number: (650) 327-3270 Website: www.corcept.com
What does Corcept Therapeutics do?

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult... patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushings syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park,...Read More

What are Corcept Therapeutics social media links?
Corcept Therapeutics Linkedin page Corcept Therapeutics Twitter page Corcept Therapeutics Facebook page
How much funding has Corcept Therapeutics raised to date?
Corcept Therapeutics has raised $119 Million in 4 funding rounds
When was the last funding round for Corcept Therapeutics?
Corcept Therapeutics closed its last funding round on Jan 27, 2011 with the amount of $41.9 Million
Who invested in Corcept Therapeutics?
Corcept Therapeutics has 9 investors including Paperboy Ventures, Sutter Hill Ventures, Alta Partners and Undisclosed.
Is Corcept Therapeutics a public company?
Yes, Corcept Therapeutics is a public company and is traded under the symbol CORT
See more information about Corcept Therapeutics

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.